Drug Proprietary Name Selection: Draft Guidance Calls For Simulation Studies

FDA recommends that drug sponsors conduct simulation studies with healthcare professionals to evaluate the safety of a proposed proprietary name for a drug product.

The agency describes how to design such studies in its draft guidance “Best Practices in Developing Proprietary Names...